LONDON – TPP Global Development has raised £9.6 million (US$13.8 million) to fund early preclinical development of programs in-licensed from universities and public research institutes, to meet the standards required by pharma. (BioWorld International)

With its lead product Rhucin (recombinant C1 inhibitor) under regulatory review in Europe and its cash balance dwindling rapidly, Pharming Group NV is battening down the hatches by spinning out DNage BV, a firm it acquired in 2006. (BioWorld International)